Actinogen Medical

Actinogen Medical is a biotechnology company developing innovative therapies for Alzheimer's disease and cognitive impairment. Our management team and scientific advisory board include world-renowned Alzheimer's and dementia researchers, as well as industry experts in drug design and clinical trial management. Actinogen Biomedical’s candidate drug, xanamem, is specifically designed to block the production of cortisol in the brain. Drugs that lower brain cortisol offer a promising new approach to slowing or even preventing Alzheimer's-related cognitive decline. Actinogen Medical is currently conducting Xanadu, an international multi-site Phase II efficacy and safety trial, for the treatment of patients with mild Alzheimer's disease.